NM_000251.3:c.1478A>T
Variant summary
Our verdict is Uncertain significance. The variant received 3 ACMG points: 4P and 1B. PM2PP3_ModerateBP6
The NM_000251.3(MSH2):c.1478A>T(p.Gln493Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000124 in 1,613,924 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q493R) has been classified as Uncertain significance.
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
 - Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
 - Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
 - mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
 - mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
 - ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
 - malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
 - prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
 - rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
 - breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
 - hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
 
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.00000657  AC: 1AN: 152234Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.00000398  AC: 1AN: 251304 AF XY:  0.00000736   show subpopulations 
GnomAD4 exome  AF:  6.84e-7  AC: 1AN: 1461690Hom.:  0  Cov.: 31 AF XY:  0.00000138  AC XY: 1AN XY: 727144 show subpopulations 
Age Distribution
GnomAD4 genome   AF:  0.00000657  AC: 1AN: 152234Hom.:  0  Cov.: 32 AF XY:  0.0000134  AC XY: 1AN XY: 74384 show subpopulations  ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5. 
Age Distribution
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome    Uncertain:2Benign:1 
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
This missense variant replaces glutamine with leucine at codon 493 of the MSH2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/251304 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Lynch syndrome 1    Uncertain:1 
- -
Lynch syndrome    Uncertain:1 
This missense variant replaces glutamine with leucine at codon 493 of the MSH2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/251304 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms    Benign:1 
- -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at